Mesenchymal Stromal Cell Therapy in MDR/XDR Tuberculosis: A Concise Review

Lavanya Joshi, Lakshmi Kiran Chelluri, Sumanlatha Gaddam*

*Corresponding author for this work

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Multi-drug-resistant (MDR) tuberculosis is a major public health problem worldwide. Drug resistance arises due to non-compliance of antibiotic therapy. Herein, we explored the therapeutic options available ranging from conservative treatment approaches to alternate adjunct therapies such as mesenchymal stromal cell (MSC) therapy interventions. It is attractive to understand the scientific rationale of using cells as drugs, in particular mesenchymal stem/stromal cells. The review dwells and attempts to analyze the mechanistic approaches of the current treatment modalities to modern therapies. MSCs have demonstrated profound capacity to regenerate and repair. They appear to modulate that the activities of dendritic cells regulate T cells, both in vivo and in vitro. While there seems to be some benefit of such therapies, its use warrants further research. The merits and de-merits of autologous therapy/allogeneic therapy are ill understood. The challenges of requirement of large number of cells for infusion, the route of administration, choice of timing are complex issues that need to be addressed. Furthermore, the host immune responses, environmental factors and epigenetic mechanisms compound the problem. Although, clinical studies are being performed using autologous MSCs in different inflammatory models, it is important that such an intervention should be based on sound scientific rationale. The current review examines the immunomodulatory properties of MSCs, its interactions with other cell types, in assessing the basis for autologous/allogeneic cell-based therapies in the treatment of XDR/MDR tuberculosis.

Original languageEnglish (US)
Pages (from-to)427-433
Number of pages7
JournalArchivum immunologiae et therapiae experimentalis
Volume63
Issue number6
DOIs
StatePublished - Jun 23 2015

Fingerprint

Multidrug-Resistant Tuberculosis
Cell- and Tissue-Based Therapy
Mesenchymal Stromal Cells
Therapeutics
Drug Resistance
Epigenomics
Dendritic Cells
Public Health
Cell Count
Anti-Bacterial Agents
T-Lymphocytes

Keywords

  • Adjunct therapy
  • Clinical trials
  • Immunomodulation
  • Mesenchymal stem cell therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

@article{a957cc5d6e0e47b6a1dcb2be765d0eb6,
title = "Mesenchymal Stromal Cell Therapy in MDR/XDR Tuberculosis: A Concise Review",
abstract = "Multi-drug-resistant (MDR) tuberculosis is a major public health problem worldwide. Drug resistance arises due to non-compliance of antibiotic therapy. Herein, we explored the therapeutic options available ranging from conservative treatment approaches to alternate adjunct therapies such as mesenchymal stromal cell (MSC) therapy interventions. It is attractive to understand the scientific rationale of using cells as drugs, in particular mesenchymal stem/stromal cells. The review dwells and attempts to analyze the mechanistic approaches of the current treatment modalities to modern therapies. MSCs have demonstrated profound capacity to regenerate and repair. They appear to modulate that the activities of dendritic cells regulate T cells, both in vivo and in vitro. While there seems to be some benefit of such therapies, its use warrants further research. The merits and de-merits of autologous therapy/allogeneic therapy are ill understood. The challenges of requirement of large number of cells for infusion, the route of administration, choice of timing are complex issues that need to be addressed. Furthermore, the host immune responses, environmental factors and epigenetic mechanisms compound the problem. Although, clinical studies are being performed using autologous MSCs in different inflammatory models, it is important that such an intervention should be based on sound scientific rationale. The current review examines the immunomodulatory properties of MSCs, its interactions with other cell types, in assessing the basis for autologous/allogeneic cell-based therapies in the treatment of XDR/MDR tuberculosis.",
keywords = "Adjunct therapy, Clinical trials, Immunomodulation, Mesenchymal stem cell therapy",
author = "Lavanya Joshi and Chelluri, {Lakshmi Kiran} and Sumanlatha Gaddam",
year = "2015",
month = "6",
day = "23",
doi = "10.1007/s00005-015-0347-9",
language = "English (US)",
volume = "63",
pages = "427--433",
journal = "Archivum Immunologiae et Therapiae Experimentalis",
issn = "0004-069X",
publisher = "Birkhauser Verlag Basel",
number = "6",

}

Mesenchymal Stromal Cell Therapy in MDR/XDR Tuberculosis : A Concise Review. / Joshi, Lavanya; Chelluri, Lakshmi Kiran; Gaddam, Sumanlatha.

In: Archivum immunologiae et therapiae experimentalis, Vol. 63, No. 6, 23.06.2015, p. 427-433.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Mesenchymal Stromal Cell Therapy in MDR/XDR Tuberculosis

T2 - A Concise Review

AU - Joshi, Lavanya

AU - Chelluri, Lakshmi Kiran

AU - Gaddam, Sumanlatha

PY - 2015/6/23

Y1 - 2015/6/23

N2 - Multi-drug-resistant (MDR) tuberculosis is a major public health problem worldwide. Drug resistance arises due to non-compliance of antibiotic therapy. Herein, we explored the therapeutic options available ranging from conservative treatment approaches to alternate adjunct therapies such as mesenchymal stromal cell (MSC) therapy interventions. It is attractive to understand the scientific rationale of using cells as drugs, in particular mesenchymal stem/stromal cells. The review dwells and attempts to analyze the mechanistic approaches of the current treatment modalities to modern therapies. MSCs have demonstrated profound capacity to regenerate and repair. They appear to modulate that the activities of dendritic cells regulate T cells, both in vivo and in vitro. While there seems to be some benefit of such therapies, its use warrants further research. The merits and de-merits of autologous therapy/allogeneic therapy are ill understood. The challenges of requirement of large number of cells for infusion, the route of administration, choice of timing are complex issues that need to be addressed. Furthermore, the host immune responses, environmental factors and epigenetic mechanisms compound the problem. Although, clinical studies are being performed using autologous MSCs in different inflammatory models, it is important that such an intervention should be based on sound scientific rationale. The current review examines the immunomodulatory properties of MSCs, its interactions with other cell types, in assessing the basis for autologous/allogeneic cell-based therapies in the treatment of XDR/MDR tuberculosis.

AB - Multi-drug-resistant (MDR) tuberculosis is a major public health problem worldwide. Drug resistance arises due to non-compliance of antibiotic therapy. Herein, we explored the therapeutic options available ranging from conservative treatment approaches to alternate adjunct therapies such as mesenchymal stromal cell (MSC) therapy interventions. It is attractive to understand the scientific rationale of using cells as drugs, in particular mesenchymal stem/stromal cells. The review dwells and attempts to analyze the mechanistic approaches of the current treatment modalities to modern therapies. MSCs have demonstrated profound capacity to regenerate and repair. They appear to modulate that the activities of dendritic cells regulate T cells, both in vivo and in vitro. While there seems to be some benefit of such therapies, its use warrants further research. The merits and de-merits of autologous therapy/allogeneic therapy are ill understood. The challenges of requirement of large number of cells for infusion, the route of administration, choice of timing are complex issues that need to be addressed. Furthermore, the host immune responses, environmental factors and epigenetic mechanisms compound the problem. Although, clinical studies are being performed using autologous MSCs in different inflammatory models, it is important that such an intervention should be based on sound scientific rationale. The current review examines the immunomodulatory properties of MSCs, its interactions with other cell types, in assessing the basis for autologous/allogeneic cell-based therapies in the treatment of XDR/MDR tuberculosis.

KW - Adjunct therapy

KW - Clinical trials

KW - Immunomodulation

KW - Mesenchymal stem cell therapy

UR - http://www.scopus.com/inward/record.url?scp=84946490310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946490310&partnerID=8YFLogxK

U2 - 10.1007/s00005-015-0347-9

DO - 10.1007/s00005-015-0347-9

M3 - Review article

C2 - 26100384

AN - SCOPUS:84946490310

VL - 63

SP - 427

EP - 433

JO - Archivum Immunologiae et Therapiae Experimentalis

JF - Archivum Immunologiae et Therapiae Experimentalis

SN - 0004-069X

IS - 6

ER -